LMR Partners’s Blueprint Medicines BPMC Stock Holding History

LMR Partners’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,600	Closed	-$240K	–	1162
2023 Q4	$240K	Buy	+2,600	New	+$168K	﹤0.01%	722

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

LMR Partners's BPMC Position: Q3 2025 in Review

LMR Partners sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 395,857 shares — an estimated $50.7M sold.

LMR Partners first reported a position in BPMC in Q1 2025 and held it in 2 quarters. The position peaked at $50.7M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

LMR Partners reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
LMR Partners sold 395,857 Blueprint Medicines shares in Q3 2025, an estimated $50.7M.
LMR Partners first reported a position in Blueprint Medicines in Q1 2025 and held it in 2 quarters.
LMR Partners's Blueprint Medicines position peaked at $50.7M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on LMR Partners's 13F filing for Q3 2025, filed 14 Nov 2025.